Generic Name:
doravirine lamuvidine tenofovir disoproxil fumarate
Project Status:
Complete
Therapeutic Area:
HIV-1 infection
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Delstrigo
Project Line:
Reimbursement Review
Project Number:
SR0581-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine, lamivudine, or tenofovir.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
HIV-1 infection
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.